David A. Scheinberg
David A. Scheinberg | |
|---|---|
| Born | David A. Scheinberg |
| Education | Cornell University BA Johns Hopkins University School of Medicine MD, PhD |
| Medical career | |
| Profession | Physician Scientist |
| Institutions | Memorial Sloan Kettering Cancer Center Weill Cornell Medicine |
David A. Scheinberg, M.D., Ph.D. is a physician, scientist, drug developer, and entrepreneur, who is currently Vincent Astor Chair, and Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK).[1] He is a pioneer and inventor of targeted alpha particle therapies and alpha particle generators for use in patients with cancer.[2][3]
Career
Scheinberg received a BA from Cornell University and an MD, PhD from Johns Hopkins University School of Medicine. He is a professor of pharmacology and co-chair of the pharmacology graduate program at Weill Cornell Graduate School of Medical Sciences and a professor at the Gerstner Sloan Kettering Graduate School. He also founded and chairs the Experimental Therapeutics Center and formerly the Nanotechnology Center at MSK. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Weill Cornell Medicine, and Rockefeller Universities.
In 2013 Nature Biotechnology recognized him as one of the top 20 Translational Scientists in the world.[4] Scheinberg has published more than 300 papers, chapters, or books and has more than 30 patents.
His laboratory studies cancer immunology, cellular engineering, cancer vaccines, T cell receptor mimic antibodies, and targeted nano-machines.
Memberships
- American Society of Clinical Investigation [5] (ASCI)
- Association of American Physicians [6] (AAP)
- Interurban Clinical Club[7]
Awards
- Doris Duke Distinguished Clinical Science Professorship
- Lucille P. Markey Scholarship
- Emil J. Freireich Award
- Leukemia and Lymphoma Society Translational Investigator Awards
- CapCure Awards
References
- ^ "At Work: Center for Experimental Therapeutics Chair David Scheinberg | Memorial Sloan Kettering Cancer Center". www.mskcc.org.
- ^ Scheinberg, D. A.; Strand, M.; Gansow, O. A. (1982-03-19). "Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies". Science. 215 (4539): 1511–1513. doi:10.1126/science.7199757. ISSN 0036-8075. PMID 7199757.
- ^ McDevitt, Michael R.; Ma, Dangshe; Lai, Lawrence T.; Simon, Jim; Borchardt, Paul; Frank, R. Keith; Wu, Karen; Pellegrini, Virginia; Curcio, Michael J. (2001-11-16). "Tumor Therapy with Targeted Atomic Nanogenerators". Science. 294 (5546): 1537–1540. doi:10.1126/science.1064126. ISSN 0036-8075. PMID 11711678.
- ^ Huggett, Brady; Paisner, Kathryn (2014-08-07). "Top 20 translational researchers in 2013". Nature Biotechnology. 32 (8): 720. doi:10.1038/nbt.2986. PMID 25101739.
- ^ "David Scheinberg ASCI".
- ^ "David Scheinberg AAP".
- ^ "Interurban Clinical Club Members".